Ovid Therapeutics (OVID) announced initiations of the Phase 2 ELEKTRA and ARCADE trials for OV935/TAK-935 in pediatric patients with rare epilepsies. The company reports that the first patient has been randomized to receive either OV935 or placebo in the ELEKTRA trial and that patient screening is underway for the ARCADE trial. These trials are being conducted together with Ovid’s collaboration partner Takeda (TKPYY).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.